Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LC16m8Δ-AAV5
- Development stage
- Preclinical
- Lead developer
- Kanazawa University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Percutaneous
01
Overview
LC16m8Δ-AAV5 is an experimental heterologous prime-boost viral-vectored vaccine regimen designed for the prevention of malaria and the blocking of parasite transmission [1003]. Developed by researchers at Kanazawa University, Jichi Medical University, and Hokkaido University, the regimen utilizes a priming dose of the highly attenuated, replication-competent vaccinia virus strain LC16m8Δ (m8Δ) followed by a booster dose of an adeno-associated virus serotype 5 (AAV5) vector. Both vectors are genetically engineered to express a fusion protein containing the pre-erythrocytic stage antigen Plasmodium falciparum circumsporozoite protein (PfCSP) and the sexual-stage transmission-blocking antigen Pfs25. In preclinical studies, this prime-boost strategy has demonstrated robust immunogenicity, eliciting high titers of functional antibodies, providing sterile protection against sporozoite challenge, and showing potent transmission-blocking activity.
- Other names
- LC16m8D-prime/AAV5-boostLC16m8Δ/AAV5m8Δ/AAV5
02
Targets
Pfs25CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on LC16m8Δ-AAV5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LC16m8Δ-AAV5.